112 related articles for article (PubMed ID: 15283134)
1. [Target molecules of molecular target therapy of cancer].
Uehara Y
Nihon Rinsho; 2004 Jul; 62(7):1206-8. PubMed ID: 15283134
[No Abstract] [Full Text] [Related]
2. On target. A new generation of drugs offers customized cures.
Fischman J
US News World Rep; 2003 Jan; 134(2):50-2, 55-6, 58. PubMed ID: 12561697
[No Abstract] [Full Text] [Related]
3. Targeted therapies in breast cancer: challenging questions from oncology nurses.
Becze E
ONS Connect; 2007; 22(8 Suppl):31-2. PubMed ID: 17824554
[No Abstract] [Full Text] [Related]
4. Avastin-Tarceva combination fails in lung cancer.
Jones D
Nat Biotechnol; 2009 Feb; 27(2):108-9. PubMed ID: 19204674
[No Abstract] [Full Text] [Related]
5. GlaxoSmithKline cancer drug threatens Herceptin market.
Waltz E
Nat Biotechnol; 2005 Dec; 23(12):1453-4. PubMed ID: 16333273
[No Abstract] [Full Text] [Related]
6. [Molecular target therapy: a milestone on the road for curing cancer].
Zeng YX; Zhang XS; Liu Q
Ai Zheng; 2008 Aug; 27(8):785-7. PubMed ID: 18710609
[TBL] [Abstract][Full Text] [Related]
7. [Some problems facing the molecular targeting therapy for colorectal cancer].
Xu JM
Zhonghua Zhong Liu Za Zhi; 2009 May; 31(5):321-3. PubMed ID: 19799077
[No Abstract] [Full Text] [Related]
8. [Resistance to target-based therapy and its circumvention].
Nishio K
Nihon Rinsho; 2004 Jul; 62(7):1343-7. PubMed ID: 15283154
[TBL] [Abstract][Full Text] [Related]
9. Targeted induction of apoptosis for cancer therapy: current progress and prospects.
Bremer E; van Dam G; Kroesen BJ; de Leij L; Helfrich W
Trends Mol Med; 2006 Aug; 12(8):382-93. PubMed ID: 16798087
[TBL] [Abstract][Full Text] [Related]
10. [Molecular diagnosis and therapy in oncology].
Baretton G; Grabbe S; Keilholz U; Sauter G
Onkologie; 2011; 34 Suppl 2():5-9. PubMed ID: 21447986
[No Abstract] [Full Text] [Related]
11. [Molecular targeting therapy for breast neoplasms].
Horiguchi J
Nihon Rinsho; 2007 Jun; 65 Suppl 6():415-21. PubMed ID: 17682186
[No Abstract] [Full Text] [Related]
12. [New development in the treatment of breast cancer. II. Future anti-HER2 therapy].
Yamashita T; Iwata K
Gan To Kagaku Ryoho; 2009 Dec; 36(13):2551-4. PubMed ID: 20104676
[No Abstract] [Full Text] [Related]
13. [Do informed patients live longer?].
Jelitto HU
Krankenpfl J; 2005; 43(4-6):142-3. PubMed ID: 16171085
[No Abstract] [Full Text] [Related]
14. Novel cancer therapies: targeting the molecules.
Gray ML; Khan S; Zimmerman R
JAAPA; 2003 Oct; 16(10):24-7, 31-2. PubMed ID: 14758674
[TBL] [Abstract][Full Text] [Related]
15. [Tyrosine kinase inhibitors in tumor therapy--part 2. Current position and perspectives].
Grimm CF; Blum HE; Geissler M
Dtsch Med Wochenschr; 2005 Jun; 130(23):1438-42. PubMed ID: 15929020
[No Abstract] [Full Text] [Related]
16. The EGF receptor family as targets for cancer therapy.
Mendelsohn J; Baselga J
Oncogene; 2000 Dec; 19(56):6550-65. PubMed ID: 11426640
[TBL] [Abstract][Full Text] [Related]
17. Advances in radiosensitization.
Lawrence TS
Clin Adv Hematol Oncol; 2004 Sep; 2(9):575-7. PubMed ID: 16163239
[No Abstract] [Full Text] [Related]
18. Lapatinib: new directions in HER2 directed therapy for early stage breast cancer.
Jo Chien A; Rugo HS
Cancer Treat Res; 2009; 151():197-215. PubMed ID: 19593514
[No Abstract] [Full Text] [Related]
19. Changes in therapy for solid tumors: potential for overcoming drug resistance in vivo with molecular targeting agents.
Kim R; Toge T
Surg Today; 2004; 34(4):293-303. PubMed ID: 15052442
[TBL] [Abstract][Full Text] [Related]
20. Cancer genome targets: RAF-ing up tumor cells to overcome oncogene addiction.
Workman P
Expert Rev Anticancer Ther; 2002 Dec; 2(6):611-4. PubMed ID: 12503197
[No Abstract] [Full Text] [Related]
[Next] [New Search]
